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Abstract: Genetic analysis is one of the fastest-growing areas of clinical diagnostics.  Fortunately, 
as our knowledge of clinically relevant genetic variants rapidly expands, so does our ability 
to detect these variants in patient samples. Increasing demand for genetic information may 
 necessitate the use of high throughput diagnostic methods as part of clinically validated testing. 
Here we provide a general overview of our current and near-future abilities to perform large-scale 
genetic testing in the clinical laboratory. First we review in detail molecular methods used for 
high throughput mutation detection, including techniques able to monitor thousands of genetic 
variants for a single patient or to genotype a single genetic variant for thousands of patients 
simultaneously.  These methods are analyzed in the context of pharmacogenomic testing in the 
clinical laboratories, with a focus on tests that are currently validated as well as those that hold 
strong promise for widespread clinical application in the near future. We further discuss the 
unique economic and clinical challenges posed by pharmacogenomic markers. Our ability to 
detect genetic variants frequently outstrips our ability to accurately interpret them in a clinical 
context, carrying implications both for test development and introduction into patient manage-
ment algorithms. These complexities must be taken into account prior to the introduction of 
any pharmacogenomic biomarker into routine clinical testing.
Keywords: high throughput, clinical laboratories, pharmacogenomics, mutation
Introduction
With the completion of the human genome project and much subsequent research, it 
has become clear that millions of loci within the human genome can vary from person 
to person.1,2 Nucleotide variation occurs not only within protein coding sequences of 
known genes but also in upstream regions, intronic sequences, and sequences far from 
any identified genes. Importantly, only a small minority of these genetic changes are 
clearly related to a given disease or phenotypic state.3 While some of these alterations 
are insertions or deletions, the majority of these variations occur as a change in a 
single nucleotide, known as single nucleotide polymorphisms (SNPs). These inherited 
SNPs typically involve just two alternative nucleotides at a given genomic position. 
These variants may be present in either heterozygous or homozygous form on the two 
chromosomal alleles that determine individual genotype (ie, A/A, A/C, or C/C). The 
most common nucleotide in a population for a given SNP is termed the major allele 
while the less frequent variant is termed the minor allele.
Our knowledge of such genomic variation among humans has grown immensely 
over the past decade. As a result, a major challenge is discerning which of these SNPs 
are clinically relevant and which are phenotypically silent. One of the major areas 
Pharmacogenomics and Personalized Medicine 2011:4submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
110
Wiita and Schrijver
of research into this allelic variation is to determine which 
genetic variants affect outcomes related to pharmacologic 
interventions. Certain sequence variations have been known 
for many years to affect drug metabolism, efficacy, or to 
increase the risk of adverse reactions, and were either 
identified by classic genetic studies or targeted mechanistic 
or experimental approaches; this gene-by-gene approach 
has traditionally formed the basis of pharmacogenetic 
studies. More recently, new advances in molecular biology 
and bioinformatics have allowed for extensive analysis 
of human nucleic acid sequence and protein expression. 
For example, genome-wide association studies have taken 
advantage of methods to analyze hundreds of thousands 
of SNPs across large populations combined with clinical 
outcomes data and comprehensive statistical methods. 
These studies have identified either individual SNPs or 
combinations of variants associated with drug response. 
In addition, expression of certain messenger ribonucleic 
acid or proteins in tumors has led to novel targeted 
therapies. These new approaches to identifying drug effects 
in relation to gene sequence and expression are termed 
pharmacogenomics.
In practice, the terms pharmacogenetics and pharma-
cogenomics are often used interchangeably. However, 
it is pharmacogenomic information derived from large-
scale genome screening that poses the biggest challenge 
for applications to the clinical laboratory: our collective 
capability to analyze SNPs in patients has often surpassed 
our ability to interpret the data in a clinically meaningful 
way. Nevertheless, there are many tests related to drug 
response that have already been incorporated into current 
clinical testing.4–6 Furthermore, it is likely that the variety 
of such tests will expand in the future as more data connect 
allelic variation, drug response, and clinical outcomes. 
As genetic variation becomes more connected to patient 
management, it is anticipated that the demand for clinical 
testing for genetic markers will increase.7 Such increased 
demand may require the testing of multiple markers in 
numerous patient samples in a rapid and parallel manner. 
In this review, we will first discuss various methods of 
identifying SNPs with high throughput in patient samples. 
We will then examine these technical advances in the 
context of practical applications to clinical diagnostics. 
This review does not attempt to comprehensively cover 
all available tests and methodologies; rather, it aims to 
provide a general framework for the current state of clini-
cal pharmacogenomic testing.
High throughput methods of 
mutation detection
“High throughput” testing of genetic variants or mutations 
can have a number of meanings, which may variously 
incorporate: (1) testing hundreds of different patient 
samples simultaneously (parallelizing), and/or (2) analyzing 
multiple genetic loci simultaneously for a single patient 
(multiplexing), and/or (3) obtaining very rapid results. The 
choice of technological method to be used for a given high 
throughput genetic test in the clinical laboratory depends 
strongly on the testing goals. Beyond technical decisions, 
bringing such a test into routine clinical diagnostics further 
requires additional, and potentially more important, 
considerations such as: (1) anticipated clinical application, 
(2) projected demand for testing (number of samples), 
(3) cost of testing, (4) complexity of establishing testing, 
and (5) regulatory status of available tests. Below we review 
examples of various available methods in the context of 
these criteria.
Large-scale multiplexing with array-based 
SNP analysis
Microarray technologies are among the best-known methods 
by which to determine SNP status, whether for pharmacog-
enomic status or disease risk factors. This approach uses 
differential hybridization of nucleic acid oligonucleotides 
to determine the presence of sequence variants. With high-
density chip deposition of standardized oligonucleotides, 
the Genome Wide SNP Array 6.0 (Affymetrix Inc, Santa 
Clara, CA) can probe for 906,600 individual SNPs8 (of 
over 10 million human SNPs identified)1 after random 
amplification and labeling of patient genomic DNA and 
subsequent hybridization. BeadArray9 technology (Illumina 
Inc, San Diego, CA) can probe 1 million SNPs using a dif-
ferent chemistry: microbeads with ligated oligonucleotides 
complementary to specific SNPs subjected to a single base 
extension reaction after hybridization. Both of these methods 
allow for hundreds of thousands of SNPs to be analyzed 
under a single set of experimental conditions with a time to 
completion of approximately 1 day.
The main drawback of these approaches is high reagent 
cost, lack of clinical utility for a subset of the markers 
analyzed, and difficulty validating each spot on the chip. In 
particular, the presence of false-negative results is difficult 
to assess without an independent patient cohort for test 
validation. In addition, this testing may be time consuming 
in terms of sample preparation with concomitant increased 
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technologist time and salary costs. Data analysis may also 
be quite involved and require a high degree of expertise in 
interpretation. Thus, while these approaches allow for great 
depth of data for a single sample, they are not economically 
feasible or practical for most clinical laboratories.
Medium-scale multiplexing with low to 
medium numbers of samples in parallel
The next approaches described are useful for probing 
approximately 10–200 pharmacogenomic markers in a 
multiplex fashion. As opposed to the whole genome SNP 
arrays described above, these tests are ordered to achieve a 
specific diagnostic goal for a given patient, which, given our 
current clinical knowledge, involves analyzing a more limited 
number of genetic changes. These methods are amenable to 
variable degrees of parallelization to accomplish probing of 
multiple patient samples simultaneously.
Selected marker microarrays
Using dedicated microarray technologies with a relatively 
small number of hybridization probes attached to the 
substrate, it is possible to probe just a few genetic markers at 
a lower cost than whole genome array technologies. Instead of 
random amplification of the entire genome, these approaches 
use an initial polymerase chain reaction (PCR) step with 
primers specific for genomic areas of interest. Differential 
hybridization is detected by array reader and proprietary 
software is used to report a genotype, sometimes with a 
corresponding clinical interpretation. Some sample modifica-
tions can be used to accommodate multiple patient samples in 
parallel. Examples include the Roche AmpliChip® CYP450 
Test10 (F Hoffmann-La Roche Ltd, Basel, Switzerland) and 
the Affymetrix DMET™ Plus.11
The arrayed primer extension technology uses a similar 
model of custom-made arrays with oligonucleotides 
complementary to genetic regions specifically amplified. 
The oligonucleotides hybridize to a point one nucleotide 
upstream of the potential variant. A single base pair 
extension reaction is carried out with fluorescence-based 
determination of nucleotide incorporation at each specific 
oligonucleotide probe. This method can be used to potentially 
genotype dozens of nucleotide variants simultaneously for 
a single patient sample.12,13 The AutoGenomics INFINITI® 
(Vista, CA) method uses a similar principle of differential 
hybridization and additional specific primer extension for 
SNP detection on an array.14 For these array-based methods 
the main drawbacks again are related to cost; the reagents 
and instruments typically are relatively expensive and the 
available clinical test menus limited.
Targeted bead-based arrays
One of the technologies frequently used is the bead-based 
array available from Luminex Corporation (Austin, TX). 
Oligonucleotides targeting the genomic areas of interest 
are covalently ligated to microspheres impregnated with 
differentially colored dyes, where each dye combination 
corresponds to a particular genetic variant. After 
hybridization with amplified patient DNA and a primer-
extension reaction incorporating a labeled mutation-specific 
oligonucleotide adapter, a genotype can be determined using 
fluorescent detection and flow cytometry. This technology 
is available for clinical testing for dozens of multiplexed 
markers performed on dozens of samples in parallel.15 While 
useful for multiplexed assays, one of the main drawbacks is 
relatively extensive hands-on time for assay preparation. An 
advantage is that this platform is open and fully customizable 
for future test development, though the number of widely 
available clinical tests is currently limited.
The Verigene® System (Nanosphere Inc, Northbrook, IL) 
is a hybrid microarray and bead-based array.16 In this system, 
fragmented genomic DNA is first hybridized to a chip substrate 
with partially complementary oligonucleotide sequences. 
Subsequently, the chip is incubated with gold nanoparticles 
functionalized with complementary DNA specific for the 
genetic variants; silver staining detects successful binding of 
gold particles. A similar technology is used in the GenMark 
Dx eSensor® system (GenMark Diagnostics Inc, Carlsbad, 
CA) with ferrocene-labeled oligonucleotides leading to 
electron transfer to a gold substrate if the specific variant is 
present.17 Whereas the Verigene system does have the advan-
tage of avoiding target amplification, unlike the GenMark 
Dx, both systems require stand-alone instrumentation and 
tests cannot be easily customized.
Targeted DNA sequencing
Direct DNA sequencing is one of the most important methods 
of probing multiple genetic variants in a single patient sample. 
Significantly, only DNA sequencing methods allow for the 
identification of novel genetic variants; all other methods 
presented here require prior knowledge of the genetic variants 
to be probed. Given the intense efforts over the past few 
years to reduce the cost of sequencing in anticipation of 
widespread whole genome sequencing, a number of different 
technologies are now becoming available. We include 
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examples of methods which demonstrate either current 
utility or promise in the near future for implementation in 
the clinical laboratory.
The most widespread sequencing technology used in 
clinical diagnostics is classic Sanger sequencing. Regions 
of interest are first amplified and polymerase-mediated 
extension then takes place in the presence of both unlabeled 
nucleotides and fluorescently labeled, extension-terminating 
nucleotides. The hundreds of extension fragments produced 
are subsequently separated by high-resolution capillary 
electrophoresis, allowing for determination of nucleotide 
sequence in read lengths over 500 base pairs. A main 
advantage of Sanger sequencing is its relative ubiquity in 
many clinical applications and laboratories, as well as its 
low error rates and relatively long read lengths. Increased 
throughput is achieved by arraying numerous electrophoresis 
capillaries in parallel using plate-based systems or by using 
various electrophoresis polymers allowing for more rapid 
fragment analysis.18
An alternative sequencing method is pyrosequencing, 
a “sequencing by synthesis” approach as opposed to the 
chain termination in Sanger sequencing. In this method, 
nucleotides are sequentially flowed into a chamber containing 
an immobilized DNA fragment and a polymerase. The 
release of a pyrophosphate molecule after incorporation into 
an elongating DNA strand is monitored using a luciferin-
luciferase system and a high-sensitivity photodiode.19 This 
method can achieve read lengths of 300–500 nucleotides 
and has been used in many clinical applications as an 
alternative to Sanger sequencing as it can be more sensitive, 
less expensive to operate per test, and largely automated to 
facilitate higher throughput.
“Next generation” sequencing methods hold great promise 
for the detection of somatic mutations. These approaches 
are capable of sequencing whole human genomes;20,21 this 
feat can now be accomplished in a few days with a cost 
in the thousands of dollars as opposed to Sanger methods 
which took years and millions of dollars.22 Whole genome 
sequencing is currently largely beyond the scope of clinical 
testing, but recent technological advances23,24 make this a 
realistic possibility in the near future.
Though multiple methods exist, here we will discuss 
two of the most established next generation technologies, 
produced by 454 Life Sciences (Roche, Branford, CT) and 
Illumina. The 454 system25 uses a bead-based approach. 
Genomic DNA is first fragmented and ligated to adapter 
oligonucleotides, which are then attached to microbeads. 
Clonal amplification in an emulsion-PCR “microreactor” 
system is then performed. The beads, each carrying a clonally 
amplified DNA fragment, are deposited onto a microtiter 
plate. Pyrosequencing and high-resolution detection is used 
to detect incorporated nucleotides for millions of DNA 
fragments in parallel. This system may allow for hundreds 
of megabases of sequence read in a 10-hour run. In the 
Illumina system,26 fragmented DNA is ligated to primers on 
a glass substrate, allowing for subsequent clonal “bridge” 
amplification. As a labeled nucleotide is incorporated into 
the expanding DNA strand, a camera reads the specific 
fluorescent color for each base. The dye is then cleaved and 
the next nucleotide added and read. Like the 454, this system 
also allows for massively parallel sequencing of thousands 
to millions of DNA fragments simultaneously.
As compared to Sanger sequencing, these next generation 
methods allow for much higher throughput of sequencing 
data. However, these next generation sequencing systems 
first appeared in versions much too expensive, too powerful, 
and too cumbersome for the clinical laboratory. Recently, 
however, both corporations have developed scaled-down 
versions (the 454 GS Junior and the Illumina MiSeq  Personal 
Sequencing System) as so-called “personal genome” 
sequencers. These instruments use chemistries similar to 
the original instruments but feature simplified workflow, less 
expensive reagents, and a faster turnaround time designed 
for applications such as targeted sequence analysis, human 
exome sequencing, or bacterial genome sequencing. Other 
methods for this smaller-scale genome sequencing are also 
emerging.
These instruments are designed and marketed to be 
used for clinical diagnostics in the near future. However, 
all these next generation sequencing methods remain to be 
comprehensively proven for clinical applications. The cost of 
the instruments and the cost of reagents per run are relatively 
high, and the experimental protocols require considerable 
hands-on time and experienced technologists. In addition, 
limitations in sequence read length and the relatively high 
error rate of base calls are of concern, especially in the 
detection of relatively rare mutations such as in cancers.
Medium to high numbers of parallel 
samples with low- to medium-scale 
multiplexing
The methods in this category comprise some of the most 
established methods for mutation analysis in clinical samples. 
These techniques are characterized by the use of specific 
reagents for the detection of one or a few nucleotide variants 
in genomic DNA. They typically can be performed using 
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instrumentation present in many clinical laboratories for a 
relatively low cost per test.
Differential primer hybridization and amplification
TaqMan® Assays (Applied Biosystems, Life Technologies 
Corporation, Carlsbad, CA) are one of the simplest and 
most widespread methods of SNP genotyping using 
differential hybridization.27 This real-time PCR method 
uses four oligonucleotides: two unmodified PCR primers 
which flank and amplify the target region of interest, and 
two short TaqMan (hydrolysis) probes which hybridize with 
different affinities to the wild-type and mutant allele to be 
investigated. In the real-time PCR cycle, one probe will bind 
specifically to its corresponding SNP site while the other 
probe will be either unstably bound or unbound to the target. 
Beginning at the PCR primer, nucleotide extension by a DNA 
polymerase with 5′ exonuclease activity will encounter the 
stably bound probe and degrade it. A dye and quencher, 
placed at opposite ends of the probe, will then diffuse apart 
and the fluorescence color corresponding to that SNP probe 
will be detected. This method allows for the simple, rapid, 
and closed-tube detection of SNP genotypes using real-time 
PCR instrumentation present in many molecular diagnostics 
laboratories. Analysis of multiple SNPs in the same tube 
is relatively limited, because spectral overlap between 
emission dyes and associated detection instrumentation 
limits large-scale multiplexing.28 However, the use of 96- and 
384-well plates allows for hundreds of samples to be easily 
tested in parallel and results can be obtained in less than 
2 hours. Using novel methods of small volume, chip-based 
reactions, Applied Biosystems has recently released the 
TaqMan OpenArray™ Genotyping System allowing for 
high throughput analysis of up to 16 SNPs simultaneously 
for 144 patients.
Another commonly used real-time PCR platform for 
mutation analysis is the LightCycler® 480 Real-Time PCR 
System (Roche).29 Whereas the LightCycler can perform 
TaqMan-style genotyping it also has the advantage of 
performing rapid melt curve analysis. In this analysis, 
one probe overlaps the genetic variant (sensor probe) 
while another binds to a nearby constant region of DNA. 
Fluorescent dyes are incorporated into the probes which 
lead to a fluorescence resonance energy transfer interaction 
when excited by an appropriate laser wavelength. As 
the temperature is gradually increased, the probe with a 
mismatched nucleotide will become unbound at a lower 
temperature, leading to a loss of fluorescence resonance 
energy transfer. This loss of fluorescence as a function of 
temperature allows for easy genotyping. Given the use of 
fluorescence and multiple oligonucleotides, this system also 
does not lend itself to large-scale multiplexing of multiple 
genetic markers in a single patient sample. However, 
the LightCycler system can be scaled up for parallel sample 
testing, ranging from 24 to 1536 samples simultaneously.
In the context of high throughput mutation detection in 
the clinical setting, turnaround time is an important factor. 
While the above TaqMan- and LightCycler-based assays only 
require approximately 1–2 hours to produce analyzable data 
once a sample is placed on the instrument, there are many 
preceding steps of DNA extraction and reaction preparation. 
Thus, these tests are typically batched and run relatively 
infrequently (eg, once a week), leading to relatively long 
turnaround times from when a sample is received. Recently, 
technologies have been developed which provide “all-in-one” 
hands-off sample preparation and real-time PCR analysis 
with results provided in under an hour from sample receipt. 
The most widespread technology is the GeneXpert System 
(Cepheid, Sunnyvale, CA). After minimal processing, a 
patient sample is added to the proprietary cartridge, where 
a microfluidic system allows for automated DNA extraction 
and subsequent real-time PCR detection of a genetic target. 
Operation of the instrument requires minimal training and 
could potentially be used either in the clinical laboratory for 
on-demand testing or even as a point-of-care test in the clinic. 
The main drawback of this approach is the relatively high cost 
of consumables with only one patient sample per cartridge, 
plus a test menu currently focused largely on microbiology 
applications.30,31
Of note, other real-time PCR systems with similar 
capabilities to those above, with many variations on 
assay design, also exist and have been applied to clinical 
diagnostics.32
Single base extension with oligonucleotide detection
Mass spectrometry methods can determine SNP genotypes 
as well. The most widespread method, MassARRAY Ana-
lyzer 4, is available from Sequenom Inc (San Diego, CA).33 
Target DNA is amplified and hybridized to specifically 
designed oligonucleotides which are complementary up to 
one base before the SNP of interest. Single base extension 
by DNA polymerase is then carried out with mass-modified 
terminator nucleotides. The resulting DNA fragments can 
subsequently be resolved by mass spectrometry methods 
given the known mass of both the oligonucleotide probe and 
the labeled terminator. Genotyping up to 40 SNPs in a single 
assay is reportedly possible, though most authors achieve 
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a lower degree of multiplexing due to primer interactions 
and inability to resolve all base variants simultaneously.34,35 
Automated methods can be used to conduct up to 384 
assays on a single matrix chip, allowing for the probing of 
hundreds of SNPs for one patient or a few SNPs for hun-
dreds of patients, facilitating high throughput. Some of the 
main benefits are the relatively simple sample preparation 
procedures, lack of fluorescently labeled reagents, and high 
accuracy of the mass spectrometry methods. Some of the 
drawbacks, however, include the expense of the necessary 
instrumentation and chip consumables, as well as the required 
time and effort to initially develop a clinical assay. In addition, 
the baseline signal must be carefully modulated to optimize 
accurate base calling.34
The SNaPshot® Multiplex System (Applied Biosystems) 
is another approach for genotyping by single base extension.36 
The principle itself is quite similar to that described for the 
MassARRAY above, though here terminator nucleotides 
are modified to incorporate specific fluorescent dyes. These 
single base extension products can then be resolved using 
capillary electrophoresis; the color of the dye incorporated 
corresponds to the nucleotide present at the variant of 
interest. Extension primers are designed with different 
lengths to denote analysis of a particular mutation. This 
system lends itself to multiplexing up to ten genetic variants 
in a single assay, and plate-based methods can be used 
for parallelization. The data from this assay are relatively 
simple to interpret, the reagents are moderately priced, and 
the assay uses instruments that may already be present in 
clinical laboratories.
Other methods
While not used in a high throughput context, restriction 
fragment length polymorphism analysis has widespread use 
in clinical laboratories. Here, mutation detection relies on 
restriction enzyme cleavage sites which are present either 
in the presence of absence of a given mutation in an ampli-
fied DNA fragment.37 In addition, traditional allele-specific 
PCR, also known as amplification refractory mutations 
system, based on primers which specifically hybridize and 
amplify only in the presence of a selected DNA variant at 
the 3′ end,38 is commonly used in many laboratories. These 
methods, though low throughput, have the advantage of 
being very inexpensive, relatively simple to perform, and 
easy to interpret, meeting the requirements of many clinical 
laboratories.
Invader™ Chemistry (Third Wave Technologies Inc, 
Madison, WI) is used in many diagnostic applications and 
uses isothermal hybridization of an “invading” probe into 
the DNA duplex followed by amplification and cleavage 
of fluorescence resonance energy transfer-based probes to 
detect the presence of a given genetic variant.39 This method 
is used in a number of laboratories, with the main drawback 
being a relatively limited test menu and relative difficulty of 
designing new assays using this technology.
Auxiliary methods to facilitate high 
throughput mutation analysis
Of note, many of the above methods only become “high 
throughput” when multiple patient samples can be tested 
in parallel. Key to this approach is the use of laboratory 
automation systems. One of the important elements is the 
use of automated DNA extraction techniques, because 
all of the above methods require purified genomic DNA. 
Manual methods for DNA extraction are laborious and 
require significant effort by laboratory personnel. Automated 
extraction leads to higher sample throughput with less 
hands-on time. Some of the above systems even can lead 
to all-in-one systems with automated DNA extraction as 
well as genotyping reaction preparation.40 Stand-alone 
automated liquid handling systems can also lead to higher 
sample throughput. These instruments can automate reagent 
pipetting and mixing, leading to decreased amounts of 
technologist time per assay, often one of the primary costs 
of any molecular test, and decreasing the scope for potential 
errors in reaction preparation. In addition, for any assay, 
instrumentation allowing multiple samples to be analyzed 
in parallel will lead to higher throughput analysis even if the 
fundamental reaction chemistry is identical.
Clinical applications of high 
throughput methods in 
pharmacogenomics
While the published literature describes the use of a 
multitude of different techniques for detecting particular 
genetic variants, many of these applications have only been 
explored in the research setting. The use of tests in the clinical 
laboratory requires extensive validation, quality control, 
and ongoing quality assessment to comply with regulatory 
mandates and to provide robust, accurate, and reproducible 
test results for patient samples. Such quality control and 
data assessment require the standard metrics of clinical 
validation including test performance compared to existing 
testing methods, presence and implications of false positives 
and false negatives, limit of detection, assay limitations, 
potential interferences, applicability of ongoing quality 
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control reference materials, indications for use, and clinical 
test interpretation. Although these validation parameters 
for laboratory-developed tests are widely used, there are 
no specific published guidelines for individual assays. The 
assays using next-generation approaches pose a particular 
challenge in this respect, given that most of these are currently 
performed in the research setting and the transition into the 
clinical setting is only recently coming about. The large 
amount of generated data in these assays poses a particular 
challenge, as does the identification of variants of unclear 
clinical significance. Specific validation guidelines for 
these novel types of assays are not yet available. In the US, 
some clinical laboratories only perform laboratory tests that 
have either been Food and Drug Administration (FDA)-
cleared as showing substantial equivalence to a previously 
approved device or fully approved by the FDA as new in vitro 
diagnostic devices. This approval process can take months 
to years and requires a significant financial investment by 
the manufacturer, but the returns from widespread clinical 
utilization are expected to justify this upfront cost. In contrast, 
many other molecular diagnostics providers rely heavily on 
laboratory-developed tests that have been both designed 
and validated in a particular clinical laboratory.41 Some of 
these tests rely on commercially manufactured, but not FDA-
cleared or approved, primers, probes, and other materials 
such as “analyte specific reagents,” whereas others are 
implemented with materials that are independently designed 
by the testing laboratory.
Below we briefly describe some of the pharmacogenomic 
test methods currently used in practice, concentrating on 
markers with known clinical utility.4,6,42 These methods are 
either described in the online test menu of various reference, 
commercial, and academic clinical laboratories or identified 
in the FDA in vitro diagnostic database.43 While this list is not 
meant to be comprehensive, it provides an overview of the 
spectrum of validated clinical applications of the molecular 
diagnostic methods discussed in previous sections.
Warfarin metabolism/CYP2C9 + vKORC1 
genotype
Warfarin is an anticoagulant used widely to prevent throm-
boses in patients at elevated risk for such events. Consistent 
dosing is well known to be difficult and it has subsequently 
been found that SNPs within the CYP2C9 gene, encoding 
one of the many CYP450 enzymes critical in hepatic metab-
olism, as well as those in the promoter of the VKORC1 gene, 
encoding the warfarin therapeutic target vitamin-K epoxide 
reductase, are strongly related to warfarin metabolism.44,45 A 
recent study showed that incorporating genotype into algo-
rithms for initiation of warfarin is necessary to normalize 
therapeutic drug levels across patients.46 Many potentially 
relevant markers have been identified in both CYP2C9 
and in VKORC1,47 though not all clinically available tests 
probe all markers. One FDA-cleared assay from TrimGen 
Corporation (Sparks, MD) incorporates multiplexed melt 
curve analysis targeting just the three polymorphisms 
with the most evidence of effect on warfarin metabolism, 
ie, the *2 and *3 variants of CYP2C9, related to warfarin 
resistance, and -1639G.A in VKORC1, related to warfarin 
sensitivity. Methods with medium levels of multiplexing 
for a single patient have also been implemented, including 
the Invader assay and the Luminex xTAG® Technology 
assay. The Verigene® Warfarin Metabolism Nucleic Acid 
Test (Nanosphere) assay is FDA-cleared for this testing,48 
as is the eSensor® Warfarin Sensitivity Test (GenMark Dx) 
targeted array.49 Of note, the ongoing European Pharma-
cogenetics of Anticoagulation Therapy trial incorporates a 
novel point-of-care, real-time PCR-based method to assess 
warfarin genotype at the initiation of therapy.50 Method com-
parisons have generally shown similar levels of accuracy 
between test methods, with the main differences occurring 
in turnaround time and cost.51,52
Clopidogrel metabolism/
CYP2C19 genotype
Clopidogrel is a highly-prescribed antiplatelet agent used 
to decrease the risk of arterial thromboses. It has been 
shown that patients with particular variants in CYP2C19 
are at increased risk of thrombosis on a standard dose of 
clopidogrel.53,54 Pharmacogenomic testing has become 
more in demand since the inclusion of an FDA “black box” 
warning recommending genetic testing prior to prescription 
of clopidogrel,55 though the utility of this recommendation 
has recently been questioned in one study focused on patients 
with acute coronary syndromes or atrial fibrillation.56 Multiple 
allelic variants have been identified in CYP2C19 which may 
be of clinical relevance, with the *1 (wild-type metabolizer), 
*2 and *3 (poor metabolizers), and *17 (ultra-rapid 
metabolizer) genotypes having the most supporting clinical 
data.56 However, some tests explore other SNPs that are rarely 
expressed, those that have less clear clinical relevance, or 
those that may relate to the metabolism of other drugs such as 
antidepressants.57,58 Given the necessity of probing multiple 
SNPs for each individual patient, multiplexed systems are 
widely used for this analysis. These include Luminex bead-
based targeted arrays which can identify the *1, *2, *3, *4, *5, 
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*6, *7, *8, and *17 genotypes, as well as targeted microarrays 
from AutoGenomics, which identify the above variants as 
well as the *9 and *10 genotypes. A single-base extension 
assay is also used and targets six allelic variants in the same 
sample. Limited comparisons showed high concordance 
between different methods.59 Table 1 shows comparison of 
current mutation screening technologies.
CYP2D6 genotyping for multiple drug 
metabolism
The CYP450 enzyme system is one of the most important 
determinants of drug metabolism in humans. One of the 
central components of this pathway is the enzyme encoded 
by the CYP2D6 gene, which plays a role in metabolizing up 
to 25% of all available medications including the anticancer 
drug tamoxifen, antidepressants, antipsychotics, opioids, and 
beta-blockers, among others.60 More than 70 alleles, which 
lead to either enhanced or decreased enzymatic expres-
sion or efficiency, have been identified in this gene.61 For 
example, studies have found that patients with a CYP2D6 
poor metabolizer phenotype demonstrate a higher probability 
of adverse drug reactions to the antipsychotics haloperidol 
and risperidone.62,63 While the clinical utility of such testing 
is still debated,64,65 the desire to genotype many CYP2D6 
markers in parallel has primarily been met with targeted 
array technologies. The Roche AmpliChip is FDA-approved 
and offered clinically; it uses a microarray with differential 
hybridization to probe 27 SNPs in CYP2D6, along with inser-
tions and deletions, as well as two SNPs in CYP2C19. The 
Luminex xTAG bead-based array system is FDA-cleared to 
probe a similar number of CYP2D6 SNPs.
Drug hypersensitivity
Some genetic variants relate to serious adverse effects 
of drug administration. Given the more limited clini-
cal demand for these tests as compared to warfarin and 
clopidogrel genotyping, they are offered by fewer clinical 
laboratories and demonstrate less need for high throughput 
methodologies.
Irinotecan is a topoisomerase II inhibitor used as a 
chemotherapeutic agent for treatment of a number of solid 
tumors. Decreased enzymatic activity of the product of the 
UGT1A1 gene is associated with decreased excretion and 
toxicity, leading to potentially life-threatening neutropenia.66 
A particular allelic variant, UGT1A1*28, consisting of 
seven TA repeats in the TATA box of the gene promoter, 
is most frequently implicated.67 In clinical testing, this 
variant is frequently identif ied by PCR and fragment 
size discrimination by capillary electrophoresis. Another 
approach is the Invader assay by Third Wave Technologies, 
which has been FDA-cleared and is offered clinically. Other 
variants in this gene also lead to decreased enzyme activity68 
and can be investigated clinically by Sanger sequencing.
Thiopurine methyltransferase is an enzyme, encoded 
by the gene TPMT, shown to relate to the metabolism 
of thiopurine drugs used in the treatment of rheumatic 
disease, organ transplantation, and lymphoblastic leukemia. 
Deficiencies in enzymatic activity are related to severe 
hypersensitivity reactions including myelosuppression and 
gastrointestinal toxicity. Red blood cell enzymatic levels are 
typically measured prior to initiating therapy, but in some 
cases TPMT genotyping can be performed instead.69 TPMT 
genotyping prior to initiation of therapy has been used to 
successfully guide drug dosing and avoid adverse effects.69 
Multiple potentially significant allelic variants have been 
identified in TPMT, with the *2, *3A, and *3C genotypes 
most clinically relevant.70 Both traditional and real-time PCR 
methods are used for clinical testing, though these techniques 
cannot easily identify all TPMT variants.69
Abacavir is a nucleoside reverse transcriptase inhibitor 
used to treat human immunodeficiency virus infection. Some 
patients using this drug develop severe, even life-threatening, 
hypersensitivity reactions. It was discovered that a large 
majority of patients with such reactions share a unique allele 
in HLA-B*5701,71 and genotyping for this allele has now 
become standard prior to starting therapy.72 Pretreatment 
screening for HLA-B*5701 has significantly decreased 
the incidence of hypersensitivity reactions.73,74 Similarly, 
hypersensitivity to carbamazepine, an antiepileptic drug, 
can lead to the life-threatening dermatologic complication 
of Stevens–Johnson syndrome. Recent studies have found 
that in East and South Asian populations, the HLA-B*1502 
allele is highly correlated with the presence of such 
severe hypersensitivity reactions.75,76 As a result, it is now 
recommended by the FDA that testing be performed prior to 
administering carbamazepine to these patients.77 The most 
common methods used to identify both the HLA-B*5701 and 
HLA-B*1502 alleles include an initial PCR step followed by 
hybridization of sequence-specific oligonucleotide probes or 
allele-specific PCR.
Hepatitis C therapy
Hepatitis C is estimated to affect approximately 200 million 
individuals worldwide, frequently leading not only to 
liver failure but also to the development of hepatocellular 
carcinoma. It had long been observed that the rate of viral 
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clearance varied widely from patient to patient using the main 
treatment modality of ribavirin with pegylated interferon-α. 
Recently, multiple genome-wide association studies inde-
pendently identified SNPs upstream of the IL28b gene as 
important predictors of response to therapy.78–80 Real-time 
PCR is the most common method for SNP identification in 
this context, with the majority of clinical laboratories testing 
for a single SNP, rs12979860, with a strong association to 
patient outcomes.81,82
Targeted oncologic therapy
With the advent of newly targeted molecular therapies, 
selected genetic variants in cancers have been shown to 
be important indicators of treatment efficacy. However, 
 compared to other pharmacogenomic variants described 
above, the sensitivity limit of detection becomes much more 
important as the mutant DNA is typically present in a back-
ground of normal cells. For germline DNA, a heterozygous 
mutation will be represented by 50% of alleles; in cancers, 
the relevant mutation may be present in under 1% of the 
examined DNA (or mRNA).83
In the treatment of non-small cell lung cancer (NSCLC), 
activating mutations in the tyrosine kinase domain of the 
EGFR gene are targeted by recently introduced small 
molecule inhibitors, erlotinib and gefitinib. The most 
common mutations, found in .90% of cases, are either a 
deletion present in exon 19 or the point mutation L858R in 
exon 21.84 For evaluation of these two specific alterations, 
many laboratories use a combination of traditional PCR 
and restriction fragment length polymorphism followed 
by capillary electrophoresis. Melt curve analysis on the 
LightCycler is also used for point mutation analysis 
in exon 21. Sensitivity of these methods needs to be 
established by each individual laboratory, but may reach 
approximately 1%–10% of mutant DNA. For evaluation 
of all described EGFR mutations,84 Sanger sequencing 
is offered widely to examine all of exons 18, 19, 20, 
and 21. While the advantage here is detection of many 
possible mutations, the drawback is the lower sensitivity 
of sequencing, which requires approximately 20% mutant 
DNA for accurate detection.
Downstream mutations in the KRAS gene have been 
shown to eliminate the therapeutic benefits derived from 
the epidermal growth factor receptor inhibitors above in 
NSCLC as well as the antiepidermal growth factor receptor 
antibodies used in colorectal cancer.5 Many alternative 
approaches are available to identify the most common 
mutations in KRAS codons 12 and 13.85 These include PCR 
with single base extension and fluorescent detection by 
capillary electrophoresis using the Mutector™ reagents from 
TrimGen (distributed by Life Technologies), allele-specific 
real-time PCR using the TheraScreen® reagents from Qiagen 
Manchester Ltd (Manchester, UK), Sanger sequencing, and 
pyrosequencing. The sequencing modalities, while typically 
less sensitive, allow additional clinically significant mutations 
to be detected, particularly those present in exon 61 of 
KRAS.85
Activating mutations in the BRAF gene also are of clinical 
importance in NSCLC as well as in many other tumors, 
including melanoma and papillary thyroid carcinoma. 
A highly promising small molecule against melanoma, 
vemurafenib, specifically targets the BRAF V600E mutant.86 
Different methods have been applied to detecting this 
mutation in BRAF, including traditional allele-specific PCR, 
allele-specific real-time PCR, and real-time PCR with melt 
curve analysis. While V600E accounts for over 90% of 
mutations in BRAF, others have also been described87 and 
can be clinically detected by sequencing methods, such as 
Sanger sequencing or pyrosequencing.
Of note, a multiplexed panel-based approach using single 
base pair extension genotyping and SNaPshot reagents 
is currently used clinically to simultaneously examine 
mutations in 13 different cancer genes in solid tumors.88 This 
panel-based approach may demonstrate additional utility as 
more targeted therapies become available. Looking forward, 
as next generation sequencing technologies become widely 
available in clinical practice, highly parallel resequencing 
of tumor exomes or targeted genomic regions could lead to 
the rapid and sensitive identification of numerous genetic 
variants in a single test.
Implications for pharmacogenomics 
and clinical diagnostics
Given the regular publication of new genome-wide 
association study analyses, our knowledge of potentially 
relevant pharmacogenomic markers is constantly evolving. 
Simultaneously, our ability to custom-tailor clinical analysis 
of genomic variants continues to improve. Optimization of 
automation and instrumentation will allow for large numbers 
of patient samples to be analyzed in a high throughput 
fashion.
However, while high throughput methodologies for 
detecting pharmacogenomic markers currently exist, many 
of these methods have only been implemented in the research 
setting.89 As evidenced by this review, for clinical laboratories, 
current levels of sample demand do not necessitate testing 
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hundreds or thousands of samples in parallel. In addition, the 
clinical utility of most highly multiplexed tests still remains 
debated. Therefore, lower-cost, lower-throughput methods 
may suffice at present.
Uncertainty regarding the utility of pharmacogenomic 
testing poses many complexities for the clinical laboratory, 
particularly in terms of laboratory economics.90 New 
publications are continually arising with the claim that a 
new SNP or group of SNPs is important in the metabolism 
or response to a given drug. However, many of these 
early suggestions from pilot studies do not ultimately 
prove to be clinically relevant when subjected to larger, 
more focused trials. The introduction of a new assay for 
pharmacogenomics-based testing may require the purchase 
of capital-intensive equipment, expensive reagents, 
and necessitates additional training of laboratory staff. 
Therefore, validation of a molecular diagnostic assay 
for a marker that ultimately proves to be of low clinical 
utility does not only fail to enhance patient care, but may 
also represent a significant financial burden and insurers 
may decline to pay for such testing. In addition, the large 
majority of clinicians have been slow to incorporate 
pharmacogenomic testing into their practices. Clinical 
laboratories will be unlikely to bring these tests online 
without appropriate demand.
In the absence of significantly increased demand most 
clinical laboratories may choose not to pursue high throughput 
analysis methods. Instead, laboratories may look to methods 
with low or intermediate throughput for the time being, 
or send pharmacogenomic testing to specialty reference 
laboratories which can take advantage of economies of 
scale. A competing force is the potential role of point-of-care 
molecular testing. One could imagine in particular a utility 
for pharmacogenomic testing in this context: genotyping 
could be performed, the results assessed, and the decision to 
prescribe a given medication made, all as part of one patient 
visit. These miniaturized and inexpensive point-of-care PCR 
systems with simple operation and rapid turn-around time 
are in various stages of development.91 Although the use of 
these instruments is in principle appealing, their convenience 
belies the complexity of the underlying pharmacogenetic 
reality and its interpretation.
Also emerging is the likely prospect of full human 
genome sequencing for under US$1000. While many 
 significant hurdles remain to be overcome, we may one day 
reach a point where the majority of patients have already had 
their genome fully sequenced before ever being prescribed 
a medication.
Future directions/Conclusion
The detection of genetic variants is clearly a rapidly evolving 
field of clinical diagnostics. The most important advances in 
this field will come from a better understanding of the clinical 
data rather than further improvements in the technologies for 
mutation detection alone. Nevertheless, the development of 
new technologies will in many ways influence and define 
the role of clinical laboratories with the advent of new 
and increasingly clinically integrated pharmacogenomic 
testing. These upcoming changes, encompassing both more 
complete clinical validation of target biomarkers as well as 
more widespread implementation of genomic analysis, will 
greatly affect the options for pharmacogenomic testing. 
Clinical laboratories must remain central to the health care 
team through consultation with treating physicians regarding 
genomic data as these methods become more widespread. 
One of the most important future developments will be 
the widespread adoption of pharmacogenomic testing into 
clinical decision algorithms. At this point the sample demand 
is likely to increase to where it is economically and practically 
feasible for a larger number of clinical molecular diagnostic 
laboratories to incorporate high throughput genome-based 
testing with a direct impact on clinical patient care.
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